Novartis moves into a "new growth cycle"
This article was originally published in Scrip
Executive Summary
Novartisis expecting its pharmaceuticals business to accelerate in the fourth quarter, when net sales should increase at a high-single digit rate, in local currencies. This is better news than expected, because lower growth had previously been forecast, commented chairman CEO Daniel Vasella.